The current HPV prophylactic vaccines consist of noninfectious, L1 recombinant HPV-like particles (VLP) (3, 4). Vaccine clinical trials have shown nearly complete protection against cervical intraepithelial neoplasia 2 or greater lesions (5-7). Neutralizing Abs are thought to be the main effectors of protection. A robust humoral response has been observed after vaccination (8 -10), and Ab levels against HPV-16 remain relatively high in the first few years after vaccination (11-13). However, length of protection afforded by vaccination is not currently known.
C ervical cancer is the second most common cancer among women worldwide (1, 2) . The recent development of prophylactic human papillomavirus (HPV) 4 vaccines provides an important new avenue for the prevention of this cancer and others linked to HPV infection.
The current HPV prophylactic vaccines consist of noninfectious, L1 recombinant HPV-like particles (VLP) (3, 4) . Vaccine clinical trials have shown nearly complete protection against cervical intraepithelial neoplasia 2 or greater lesions (5) (6) (7) . Neutralizing Abs are thought to be the main effectors of protection. A robust humoral response has been observed after vaccination (8 -10) , and Ab levels against HPV-16 remain relatively high in the first few years after vaccination (11) (12) (13) . However, length of protection afforded by vaccination is not currently known.
Studies by our group and others have shown that in addition to Ab responses, strong cell-mediated immune responses are observed after vaccination (14 -17) . It is known that cell-mediated immune responses are required for Ab production and for maintenance of Ab levels over time. Thus, it could be postulated that the patterns of innate and acquired cellular immune responses following initial vaccination might influence Ab responses and duration of protection afforded by vaccination (18, 19) . A better understanding of these early responses to vaccination might help elucidate mechanisms of vaccine protection via neutralizing Abs, and assist in the identification of early markers of long-lasting vaccine responses.
Microarray analysis has been applied to determine gene expression patterns in studies of disease pathogenesis (20 -23) , immune response to infection (24 -30) , and immune response after immunization (31, 32) . However, few studies have looked at vaccineinduced responses in humans (33) (34) (35) .
To characterize the immune response to HPV-16 L1 VLP vaccination, we used microarray chips that cover 8638 verified sequences to investigate the gene profile associated with a recall response to the vaccine in leukocytes from vaccine recipients. We identified probesets that were differentially expressed in PBMCs from vaccine recipients after in vitro stimulation with HPV-16 L1 VLP compared with pre-vaccination samples. We also analyzed the "primary" response to HPV-16 L1 VLP, independent of vaccination, by comparing the gene expression pattern of cells incubated with HPV-16 L1 VLP and unstimulated cells, using prevaccination samples.
Additionally, the correlation of gene expression to neutralizing Ab titers developed after vaccination was examined to evaluate potential determinants of strong Ab responses. Key results were confirmed by RT-PCR in an independent set of vaccinated individuals.
This is the first study that evaluates the immune response to an HPV VLP vaccine using microarray technology. Our results contribute to a broader understanding of the effects of vaccination with a monovalent HPV-16 L1 VLP vaccine. The approach used herein and the gene expression profile defined in this study may prove to be useful for future prediction of long-term HPV vaccination outcomes in ongoing clinical trials.
Materials and Methods

Study design
Participants were selected from a double-blind, randomized, placebo-controlled phase II trial of a monovalent HPV-16 L1 VLP vaccine without adjuvant, which was conducted in a sample of 220 healthy, HIV-seronegative adult female volunteers 18 -25 years of age, as described previously (17) . Briefly, subjects were enrolled at The Johns Hopkins University Center for Immunization Research (Baltimore, MD). Prevaccination HPV-16 Ab or DNA status was not a criterion for eligibility into the trial. Subjects were determined by history to be at low risk for HPV-16 exposure. Individuals were not eligible to participate if they had a history of more than four lifetime sexual partners or more than two sexual partners within the preceding 6 mo. Additional exclusion criteria included history of abnormal cervical cytology, immunodeficiency, anaphylaxis to medicines or vaccines, receipt of blood products within 3 mo of enrollment, current pregnancy or lactation, and any other condition that might interfere with the study objectives. Women were randomly assigned to receive three i.m. doses of either 50 g of HPV-16 L1 VLP vaccine without adjuvant, or placebo (0.5 ml saline). Blood specimens were collected before the initial dose (month 0) and 1 mo after each of the subsequent vaccinations (months 2 and 7). The Johns Hopkins University Institutional Review Board approved the protocol for this study. Blood specimens were shipped to the HPV Immunology Laboratory (Frederick, MD), where PBMCs were cryopreserved.
Twenty-seven subjects (20 vaccine and 7 placebo recipients) were randomly selected for microarray measurements. Only month 0 and month 2 samples were selected for this study because earlier findings indicated that the largest increases in cytokine responses were typically observed at month 2 (17) . Month 0 and 2 samples from 10 additional vaccine recipients were selected for a second, confirmatory phase of our study by RT-PCR.
HPV-16 L1 VLP vaccine
HPV-16 L1 VLPs were expressed in baculovirus-infected Sf9 insect cells (Novavax). Production of clinical lots of recombinant HPV-16 L1 VLP vaccines was performed in accordance with Good Manufacturing Practices guidelines as previously reported (36) . The VLPs used in vitro to stimulate PBMCs were similar to the ones used to vaccinate the subjects included in this study. VLPs were provided at 1 mg/ml, stored at Ϫ80°C, and thawed immediately preceding in vitro stimulation, as previously described (16) .
PBMC incubation and microarray analysis
Cryopreserved PBMCs were thawed and cultured (2.0 ϫ 10 6 cells/ml) as previously described (17) . PBMCs (10 ϫ 10 6 ) were plated in each well of a 6-well plate (Costar) in RPMI 1640 medium supplemented with penicillin-streptomycin (100 g/ml-100 U/ml; Invitrogen), L-glutamine (2 mM), HEPES buffer (10 mM), and 10% heat-inactivated FCS (HyClone). Cells were cultured for 72 h at 37°C with media, HPV-16 L1 VLP (2.5 g/ml), or Sf9/baculovirus insect cell lysate (0.1 g/ml; Novavax), all diluted in cell culture media. Media was used as a background measurement for untreated cells. The Sf9/baculovirus insect cell lysate was used as a control Ag for the L1 VLP production system.
A total of eight incubations were set up on the same day for each subject. Incubations for two subjects were set up on the same day. The order of sample preparation was randomly defined from the list of selected subjects.
When harvesting, cultures were centrifuged and cell-free supernatants were aliquoted and frozen at Ϫ80°C. Total RNA extracts were performed using an RNeasy Total RNA isolation kit (Qiagen). RLT lysis buffer was quickly added to the culture well and then to the cell pellet to include both adherent and suspension cells. RNA purity and integrity were tested by microcapillary electrophoresis using the Agilent 2100 bioanalyzer (Agilent Technologies).
Microarray gene expression analysis was performed using the human genome focus array from the Affymetrix GeneChip system (Affymetrix) that contains ϳ8700 probesets to 8638 characterized human genes. Total RNA preparation and labeled cRNA synthesis and hybridization were performed according to the manufacturer's recommended protocol (Affymetrix). In short, 10 g of total RNA was used for double-stranded cDNA (ds-cDNA) synthesis with the SuperScript II reverse transcriptase kit (Invitrogen) and an oligo(dT) primer containing a T7 RNA polymerase promoter to prime the first-strand synthesis. Biotin-labeled cRNA was obtained by in vitro transcription after addition of T7 RNA polymerase and biotinylated nucleotides (Enzo Biochem) to the ds-cDNA. Labeled cRNA was fragmented and hybridized to the GeneChips, which were then washed and stained with streptavidin-conjugated PE by using the Affymetrix GeneChip fluid station 400. To assess the quality of hybridization, the following quality control filters were used: scaling factor, background, percentage of present calls, noise, housekeeping genes (3Ј/5Ј ratios and intensity for GAPDH and actin), RNA degradation slope, and presence or absence of internal spike controls.
Gene expression levels were determined by laser scanning of the GeneChip at 570 nm and were log 2 -transformed following MAS5 probeset summarization. All results from a donor were excluded if one of the conditions (media and VLP cultures for the pre-and postvaccination specimens) did not fulfill one of the previously mentioned quality control filters used to ensure that all chips were of comparable quality. These quality control procedures resulted in exclusion of two of the vaccine recipients and one placebo. One additional vaccine recipient was excluded due to a high degree of granulocyte contamination (61% vs 0.2-13.6% granulocytes for remaining samples), possibly due to poor PBMC Ficoll isolation, and because neutralizing Abs against HPV-16 were detectable before vaccination. Two additional placebos were excluded because they had detectable Abs in the course of our study. After all exclusions, 17 vaccine and 4 placebo recipients were used in subsequent analysis.
Data from probesets that were not reliably detected with a mean intensity more than log 2 of 5 in at least one experimental condition (media and VLP cultures for the pre-and postvaccination specimens) were excluded before further analysis. A total of 7145 probesets remained after applying this criterion.
The data discussed in this publication have been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) (37) and are accessible through GEO series accession no. GSE13587 (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc).
Flow cytometry
Major lymphocyte subsets for all samples were determined by flow cytometry (FC-500, Beckman Coulter), as previously described (38) . Flow cytometric analysis of main lymphocyte subsets indicated that overall levels of major lymphocyte subsets did not change considerably after vaccination (mean ϩ SD pre-vs postvaccination were: CD3 ϩ cells, 78 Ϯ 7 vs 77 Ϯ 9; CD19 ϩ cells, 10 Ϯ 6 vs 10 ϩ 5; CD16 ϩ /56 ϩ cells, 11 Ϯ 6 vs 11 Ϯ 6). Additionally, placebo recipients had also similar overall levels of leukocyte subsets (mean Ϯ SD month 0 vs month 2 were: CD3 cells, 77 Ϯ 4 vs 79 Ϯ 5; CD19 cells, 11 Ϯ 3 vs 11 Ϯ 6; CD16 ϩ /CD56 ϩ cells 9 Ϯ 1 vs 8 Ϯ 3).
Neutralizing Abs
HPV-16-neutralizing Ab titers were determined using a pseudovirus-based neutralization assay performed as previously described (39) . Serum neutralization titers were defined as the reciprocal of the highest dilution that caused at least 50% reduction in secreted alkaline phosphatase activity. A negative control using the bovine papillomavirus pseudovirus was performed for all samples. Undetectable Ab levels were considered as 0. All individuals selected for the microarray analysis had no detectable Abs before vaccination. After vaccination, all individuals developed Ab titers against HPV-16 (month 2 mean titer, 843 Ϯ 748, range, 78 -2602; month 7 mean titer, 5209 Ϯ 7383, range, 111-25,571; month 12 mean titer, 2366 Ϯ 4184, range, 148 -15,317).
Quantitative real-time PCR and confirmation of microarray results
Real-time PCR measurements were performed with samples from 10 independent vaccine recipients collected at month 0 and month 2 postvaccination within this same clinical trial. These individuals were selected randomly based on availability of cryopreserved PBMCs at both time points and were not tested by microarray. One subject was excluded from analysis because anti-HPV-16-neutralizing Abs were detectable before vaccination. All remaining nine donors had no detectable neutralizing Ab titers before vaccination and thus a similar prevaccination Ab status as the individuals used for the microarray experiments. Additionally, an induction in anti-HPV-16 titers was observed at month 2 after the first dose (mean titer at month 2, 2675 Ϯ 2644, neutralizing titer range, 333-8508).
A total of 22 probesets (see Table V ) were selected for confirmation. All selected probesets had an average fold induction of 2.0 or higher by microarray (range, 2.0 -5.0), which was observed in at least 50% of subjects (range, 50 -83%). Ten selected probesets had statistically significant differences before and after vaccination with significance levels of p Յ 0.001. These included GZMB, IFNG, HSD11B1, INDO, GGTLA1, KIF20A, GOLPH2, IL6, IL3, and AICDA. The remaining 12 probesets were selected either because their expression levels correlated with Ab titers at month 7 or 12 (r Ͼ 0.52; five probesets: CYP27B1, INHBA, MMP12, CD1B, and CCL7) or they were cytokines/chemokines of potential interest (seven probesets: CSF2, IL2, IL5, CXCL13, LTA, LIF, and CCL13).
PBMC incubation and total RNA extraction were performed as described above. One microgram of total RNA extract was reverse-transcribed with random hexamer primers, using SuperScript reverse transcriptase (Invitrogen). One-twentieth of the first-strand cDNA synthesis reaction was used as template. Predesigned primer and probe kits (TaqMan gene expression assays; Applied Biosystems) and the TaqMan universal PCR master mix (Applied Biosystems) were used according to manufacturers' recommendations. Briefly, stock reaction solutions were prepared by mixing 10 l of PCR master mix (2ϫ), 1 l of primer kit (20ϫ), and 7.1 l of diethyl pyrocarbonate-treated water per reaction. Stock solution (18.1 l) was dispensed to each well, and 1.9 l of cDNA was then added (total volume per reaction of 20 l). The following temperature program was used for all genes: 2 min at 52°C, 10 min at 95°C, and 50 cycles of 15 s at 95°C and 1 min at 60°C. Fluorescence intensity was measured in real time during the extension step using the iCycler IQ multicolor real-time PCR detection system (Bio-Rad). The following formula was used to determine fold induction for each gene:
here CtXVpost indicates threshold cycle of the analyzed gene in month 2 cells treated with VLP; CtRVpost, threshold cycle of RPLPO (acidic ribosomal phosphoprotein P0 subunit) in month 2 cells treated with VLP; CtXMpost, threshold cycle of the analyzed gene in month 2 cells treated with media; CtRMpost, threshold cycle of RPLPO in month 2 cells treated with media; CtXVpre, threshold cycle of the analyzed gene in month 0 cells treated with VLP; CtRVpre, threshold cycle of RPLPO in month 0 cells treated with VLP; CtXMpre, threshold cycle of the analyzed gene in month 0 cells treated with media; and CtRMpre, threshold cycle of RPLPO in month 0 cells treated with media.
To determine the cutoff value for PCR results, the fold change for RPLPO was calculated as follows:
This was used to determine variability of RPLPO for all subjects and to define the lowest fold change to consider a gene as up-regulated. Based on this, only genes with a fold change higher than the average plus two SDs of the value obtained for RPLPO were considered positive (i.e., 2.14-fold change).
Data analysis
To determine vaccination-induced changes, gene expression levels (presented as log 2 of intensity) for each probeset were compared before and after vaccination. Media-incubated expression levels were subtracted from VLP-incubated samples to adjust for background noise. Paired t tests comparing the mean before and after vaccination were used to determine statistical significance. To account for the evaluation of the large number of genes, p values of Ͻ0.001 were considered significant. Furthermore, only probesets with log 2 expression change (n-fold) Յ1.3 (down-regulated) or Ͼ1.3 (up-regulated) were considered. For the a priori analysis, changes in gene expression for a predefined set of probesets within preselected pathways (defense, inflammation, cytokine, IFN, cell cycle, signal transduction) were evaluated. The selection of probesets was based on the list of gene ontology pathways obtained for the probesets present in the human genome focus array. A p value of Ͻ0.001 (and fold change Ͼ1.3) was used to define a significantly differentially expressed probeset. The probesets were then mapped to our a priori list of probesets in pathways of interest. The rates of differential expression in these pathways were compared with the rates of differential expression among nonpathway probesets. Gene set analysis, a permutation-based approach, was used to compute p values for the predefined gene sets (25) .
We compared the direction and magnitude of expression values from the vaccine recipients to that from four placebos to ensure that effects seen in vaccinated women were specific and not observed among placebo controls. Since the number of placebo recipients was small, we relied on the magnitude of effect rather than statistical significance to determine the specificity of findings among vaccinated women.
For the exploratory analyses, functional annotation and biological term enrichment analysis of regulated probesets were performed by using the DAVID knowledge base (40) . This approach assumes independence under the null hypothesis.
Expression values for PBMCs incubated in culture media were evaluated before and after vaccination for background measurements. Gene expression values of VLP-treated cells were corrected for background by subtracting results from unstimulated cells. Paired t tests were conducted to compare expression levels for each probeset before and after vaccination. All probesets that were differentially expressed at a significance level of p Ͻ 0.05 (and fold change Ͼ1.3) were considered, including the 113 probesets that were significant at p Ͻ 0.001 (and fold change Ͼ1.3). Since the purpose of this post hoc evaluation was of an exploratory nature, we used a high p value threshold to define probesets of interest and did not adjust for multiple comparisons. Functional annotation of the differentially expressed probesets was performed using DAVID version 2.0 (41).
To determine whether there is an association between gene expression and Ab levels for differentially expressed probesets, we calculated the Spearman correlation of the difference in expression levels post-and prevaccination (corrected for background, as summarized above) with neutralizing Ab titers at months 2, 7, and 12.
Results
Evaluation of differential response to HPV-16 L1 VLP stimulation induced by vaccination
The main aim of our study was to determine changes in gene expression that are associated with HPV vaccination. To this end, we compared gene expression levels in PBMCs from vaccine recipients obtained before vaccination and 1 mo after the second vaccine dose (month 2). After filtering, we observed that overall 128 of 7145 probesets (1.8%) were found to be significantly differentially expressed after vaccination ( p Ͻ 0.001). Among these, 113 probesets met the fold-change criteria (fold-change Ͼ1.3). Of these, 63 (56%) were up-regulated and 50 (44%) were down-regulated. None of these probesets were significantly differentially expressed in baculovirus-treated cultures following vaccination, when compared with levels in baculovirus-treated prevaccination samples (all p values were Ͼ0.001, data not shown). Also, with the exception of probeset PLA2G4B, none of these probesets demonstrated evidence of differential expression of comparable magnitude among the placebo subjects evaluated (data not shown).
Forty-eight of the 113 significantly differentiated probesets mapped within the 2345 probesets identified within the six pathways targeted for our a priori analysis (cell cycle, cytokines, defense, inflammation, IFN response, and cell signaling). As shown in Table I , the percentage of differentially expressed probesets was significantly increased in the cell cycle (1.7 fold, p Ͻ 0.001), cytokine (2.3-fold, p ϭ 0.002), defense (2.7-fold, p ϭ 0.002), inflammation (3.0-fold, p ϭ 0.004), and IFN (4.6-fold, p ϭ 0.037) pathways when compared with rates of differential expression among the 4800 probesets that did not map to probesets within a priori pathways (1.4%). The lists of significantly differentially expressed probesets ( p Ͻ 0.001) within these a priori pathways are presented in Table II . The most significant up-regulated probesets were RRM2 (cell cycle pathway), CTSC (defense pathway), IFNG (cytokine and defense pathways), RFC3 (cell cycle pathway), and INDO (defense and IFN pathways), and the most significant downregulated probesets were TSC1 (cell cycle pathway), CD14 (defense and inflammation pathways), ADORA2B and DPP4 (defense pathway), as well as GRN (cytokine pathway). A similar list for the pathway that did not have significant evidence for enrichment in our a priori evaluation (cell signaling) is presented in supplemental Table I . 5 The list of significantly differentially expressed probesets not within one of our a priori pathways is shown in supplemental Table II . A summary of overall gene expression profiles induced by vaccination ( p Ͻ 0.001) is summarized in Fig. 1 . Biological term enrichment analysis was performed using DAVID. In addition to the above a priori pathways, the following were found to have evidence for enrichment: up-regulated pathways-receptor binding (nine probesets), catabolism (nine probesets), hemopoietic or lymphoid cell development (four probesets), cell death (eight probesets), and peptidase activity (eight probesets); down-regulated pathways-programmed cell death (seven probesets), phosphoric ester hydrolase (four probesets), and alcohol metabolism (four probesets).
For our exploratory analysis, we expanded the evaluation to probesets differentially expressed at a p Ͻ 0.05 cutoff level, and 624 of 7145 probesets (8.7%) were found to be differentially expressed (330 up-regulated, and 294 down-regulated; Table III) .
Correlation of gene expression with neutralizing Ab titers after vaccination
Durability of protection after vaccination has not been established, but it is possible that individuals developing higher neutralizing titers upon immunization will have longer lasting protection against HPV infection. If so, understanding the immunological profile of individuals who develop higher neutralizing titers upon immunization might help elucidate the molecular mechanisms of long-term protection. With this in mind, we compared probeset expression levels induced by vaccination against neutralizing titers at 1 mo after second vaccination (month 2) and 1 or 6 mo after the third vaccination (month 7 or 12, respectively). Only individuals negative for neutralizing Abs before vaccination were included. For this analysis, we considered the subset of 624 probesets that were differentially expressed at a p Ͻ 0.05.
Correlations were typically lower when vaccination-induced changes in probeset expression levels (measured at month 2) were compared against neutralizing Ab levels at month 2 (98% of correlations were between Ϫ0.50 and ϩ0.50 at month 2, compared with 87% when month 7 and 84% when month 12 neutralizing Ab levels were used). Table IV summarizes results for the subset of 22 probesets observed to have a correlation with neutralizing Abs of Ͼ0.60 or ϽϪ0.60 at both month 7 and month 12 after vaccination. A complete list of results is provided in supplemental Table III . The highest positive correlations at both month 7 and month 12 after vaccination correlation (Ͼ0.70 at both time points) was observed for the following probesets: CCND2 (month 7, r ϭ 0.88; month 12, r ϭ 0.82), LGALS2 (month 7, r ϭ 0.86; month 12, r ϭ 0.74), and IL1RN (month 7, r ϭ 0.75; month 12, r ϭ 0.73). 5 The online version of this article contains supplemental material. 
Confirmation of a subset of differentially expressed genes by quantitative RT-PCR
To confirm the microarray results, a subset of 22 differentially expressed genes (defined in Materials and Methods) was selected for confirmation by PCR using samples from an independent group of vaccine recipients (n ϭ 9). As shown in Table V , the expression pattern of the selected genes concurred with the microarray data for 15 of 22 of the analyzed probesets (GZMB, IFNG, HSD11B1, INDO, IL6, IL3, CSF2, CYP27B1, IL2, IL5, INHBA, MMP12 , CD1B, CCL7, and LIF). For a smaller group of six probesets, the frequency of up-regulated probesets was lower using PCR than was observed with microarray (GGTLA1, KIF20A, AICDA, CXCL13, LTA, and CCL13). Finally, no up-regulation (mean fold change, 1.4) was detected by PCR for one of the selected probesets (GOLPH2), while 61% of samples showed an up-regulation by microarray analysis. Table IV ). An additional 258 probesets were differentially expressed at the 0.001Ͻ p Ͻ 0.05 level (154 upregulated, 104 down-regulated). Pathway enrichment evaluation was suggestive of enrichment for probesets mapping to genes from inflammatory, immune response, chemotaxis, signal transduction, and cell proliferation pathways, as summarized in Fig. 2 . Interestingly, at least 26 of the 260 up-regulated probesets are IFN-induced genes or play a role in IFN signaling. There was an overlap between the probesets directly induced by HPV-16 L1 VLP before vaccination and those differentially expressed in postvaccination samples (n ϭ 91 or 9 up-regulated probesets and 45 or 7 downregulated probesets when using p Ͻ 0.05 or p Ͻ 0.001, respectively; Fig. 3 ). The overlapped probesets belong to the most enriched pathways observed in HPV-16 L1 VLP-treated PBMCs (for example, IFN-␥, IL-6, granzyme B, INDO, and several chemokines). The up-regulated, overlapping probesets significant at p Ͻ 0.001 were INDO, LAMP3, TYMS, ALAS1, RRM2, CD38, IL6, IFNG, and AKAP2. Down-regulated overlapping probesets significant at p Ͻ 0.001 included CD9, HS3ST2, SORL1, ADFP, DFNA5, EPAS1, and ALDH3A2. A complete list of overlapping differentially expressed probesets is shown in supplemental Table IV .
Analysis of prevaccination response to HPV-16 L1 VLP
Discussion
In this study, we characterized the gene expression pattern of recall immune responses to the HPV-16 L1 VLP by comparing pre-and postvaccination gene expression patterns of PBMCs incubated with HPV-16 L1 VLP Ag to better characterize the cellular and innate immune responses in vaccination against HPV. Although the effector mechanism of protection for this vaccine is thought to be neutralizing Abs, our results show that multiple pathways within the cellular and innate arms of the immune system are targeted upon vaccination. The exact role of these pathways in protection or duration of protection is still unknown, but based on the results presented herein it deserves further investigation. The analysis of correlation between differentially expressed genes and neutralizing Ab levels allowed us to identify genes (in particular CCND2, LGALS2, and IL-1RN) that may be predictors of prolonged Ab responses. New studies are necessary to better determine which pre-and postvaccination clinical, immunological, and expression profiles are most associated with long-term protection against HPV.
We took two different approaches to data analysis: a conservative approach that takes into account the potential high false discovery rate that may accompany the high number of statistical comparisons performed, and an exploratory approach to define additional biological pathways and probesets altered in a recall immune response to the vaccine. Using the conservative approach, we preselected pathways based on overall knowledge of microbial immune responses. This reduced the number of comparisons made and focused our analysis on the strongest a priori pathways expected to be involved in immune responses to vaccination. Our results suggest that the response to HPV-16 L1 VLP in vaccine recipients involves modulation of genes within the cell cycle, cytokine, defense, inflammation, and IFN pathways. This finding is consistent with the induction of various arms of the immune response (42, 43) and with our previous data that a recall response to HPV-16 L1 VLP involves a broad and complex pattern of cytokines and chemokines (16, 17) .
No significant enrichment was observed for the signal transduction pathway in our conservative analysis despite differential expression in genes that belonged to this pathway. A possible explanation for this observation might be that the definition of this pathway is broad (1577 probesets), and that the differentially expressed probesets within the pathway represent a small subset of the total number. In our exploratory analysis, the signal transduction pathway was found to be overrepresented. This information may be used for hypothesis generation in future studies.
Within the pathways evaluated, we identified up-regulation of genes involved in cytotoxic (CTSC, GZMA, GZMB, TNFSF10, FASLG) and important immunoregulatory functions (INDO, HSD11B1, CTLA4, SOCS1). These results suggest that the immune response to HPV-16 L1 VLP induces a complex modulation of various components of the cell-mediated immune response, including cytokine secretion, cytotoxic response, and activation of feedback mechanisms involving immunoregulatory genes. These results raise the need for future studies determining the contributing roles of these pathways in immunogenicity induced by VLPs. A better understanding of these pathways may be also useful in the design of improved vaccine strategies. Additionally, a substantial fraction of the differentially expressed probesets was down-regulated after vaccination, including genes that fell into cell death, immune response, signaling, and metabolism pathways. Because we used PBMCs, the transcriptional change is representative of the changes from various cell types comprising the PBMC population and the cross-talk of extracellular signals, such as cytokines induced directly or indirectly by the VLPs. Interestingly, expression of a number of these down-regulated genes and corresponding proteins, such as CD9, CD14, ly86, LEF-1, and CD26, have been shown to be down-modulated in the context of cell activation and/or inflammatory signals (44 -47) . Such changes may relate to the shutting down of specific elements to better mount a protective immune response to HPV vaccine and avoid excessive inflammatory signals or limit feedback signaling. However, the underlying mechanisms and impact of these transcriptional changes in the development of an immune response to vaccination are not known.
When we examined the correlation of probeset expression levels with neutralizing Ab titers, more probesets correlated to Ab levels at months 7 and 12 postvaccination than at month 2. The highest correlations at month 7 and month 12 were obtained for cyclin D2 (CCND2), which plays an essential role controlling the cell cycle at the G 1 /S transition (48); galectin 2 (LGALS2), a galactosidebinding lectin that has been shown to promote apoptosis in activated T cells and to shift immune responses to a Th2 profile (49); and IL-1 receptor antagonist (IL-1RN), a regulator of IL-1 induced inflammatory response. In fact, cyclin D2 and AICDA are components of signaling cascades needed for B cell proliferation and Ab production (50, 51) . However, the potential role of galectin-2 and IL-1 receptor antagonist in B cell responses is unclear and could be of an indirect nature since these are immune regulatory molecules. Confirmation of the role of the products of these genes in B cell memory responses to the vaccine would be informative in the future.
To confirm the microarray results, we selected PBMCs from an independent group of vaccine recipients and measured RNA expression for a subset of 22 probesets representing various biological pathways targeted by vaccination. We observed a comparable frequency of responders for 68% of analyzed genes (15 of 22) . For an additional 27% (6 of 22) of analyzed genes, differential expression was similar to that observed by microarray testing, but at a lower frequency. We were unable to observe evidence of differential expression as noted by microarray for 1 of the 22 selected genes. These results validate our microarray findings and suggest that the HPV-16 L1 VLP-specific response after vaccination involves activation of a complex cell-mediated immune response.
Our results demonstrate that the immune response to vaccination is heterogeneous among vaccine recipients at the gene expression level. For all the probesets analyzed, only a fraction of the participants were considered responders when looking at one gene at a time. The highest frequency was observed for HSD11B1 (15 of 18 donors in microarray, and 7 of 8 with RT-PCR). However, when "responders" are defined by the global expression profile of multiple genes at one time, the response rate is high (data not shown). Whether this heterogeneity of response will have an impact on long-term memory and quality of the immune responses over time needs to be addressed in further studies. It is possible that heterogeneity of response may be associated with previous exposures to HPV. Studies of comparison of expression profiles induced by vaccination in naturally infected vs naive individuals are warranted. Additionally, identification of gene signatures associated with infection or vaccination will also be important.
In addition to the evaluation of vaccine-specific immune responses, we characterized the vaccination-independent responses to VLP by comparing HPV-16 L1 VLP-incubated cells with media controls in prevaccination samples. Our analysis revealed that incubation with HPV-16 L1 VLP before vaccination induces upregulation of the defense response, cytokine/inflammation, signal transduction, and cell proliferation pathways. If the responses elicited by HPV-16 L1 VLP in the post-and prevaccination responses are compared, ϳ30% of the probesets modulated by VLP (136 out of 397; p Ͻ 0.05) before vaccination overlap with the HPV-16 L1 VLP-specific responses induced by vaccination. Interestingly, for most of the overlapping probesets, responses observed after incubation with HPV-16 L1 VLP are stronger than before vaccination. This probably reflects an increase in the number of responding cells after vaccination. In contrast to the vaccination-specific responses, a strong induction of an IFN response was observed in the vaccination-independent responses. These findings are important considering the current potential applications of VLP as vectors for Ag delivery and as vaccines for various pathogens and tumors (52) .
PBMCs are a valuable tool to study immune responses to various diseases (29, 30, 53) . Use of PBMCs, however, has some limitations that need to be taken into account. PBMCs are heterogeneous in their cell composition. For this reason, an enhanced or reduced gene expression might be restricted to particular cell populations. Additionally, the response to stimulation with HPV-16 L1 VLP in an ex vivo system might differ from responses that occur in disease-relevant tissues. Also, since the number of memory cells in PBMCs is low, a recall response could be diluted by the response from other cell populations. Thus, it is conceivable that large alterations in the expression of a unique gene from an underrepresented cell type may be overlooked upon examination of the PBMC population. Despite these considerations, we confirmed a group of genes using RT-PCR analysis, and a good correlation for a number of genes with neutralizing Ab levels was observed. Moreover, we found no correlation between levels of gene expression and the percentage of leukocyte subpopulations, suggesting that differences seen were not likely to be due to changes in cell populations. In fact, flow cytometric analysis of main lymphocyte subsets revealed no major cell subset differences between baseline (month 0) and month 2 samples.
An additional potential limitation of our study is the fact that results observed may not be directly extrapolated to patterns that will be obtained after vaccination with the commercially available HPV L1 VLP vaccines, because participants in our study were immunized with HPV-16 L1VLP without an adjuvant. Additionally, the HPV-16 L1 VLP vaccine used in our study is monovalent and produced in a recombinant baculovirus system. However, our results provide interesting and unique information on HPV-16 L1 VLP-specific changes, independent of adjuvant effects.
In conclusion, we used gene expression profiling to identify important adaptive and innate immune responses induced by vaccination with HPV-16 L1 VLP vaccine. We also identified differentially expressed genes predictive of neutralizing Ab titers. Interestingly, the host transcriptional response to HPV-16 L1 VLPs following vaccination varies considerably among donors, raising the need for further studies to better understand the potential impact of those differences in APC function, T cell and B cell responses, and how these gene signatures predict immunogenicity and long-term outcome.
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